Anti-CD137 antibodies and uses thereof
AssigneeAlligator Bioscience AB
InventorsPeter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
Claims18
An antibody or an antigen-binding fragment thereof with binding specificity for domain 2 of human CD137 wherein the antibody or antigen-binding fragment is a CD137 agonist and is capable of inhibiting the binding of reference antibody ‘1630/1631’ to human CD137, and wherein the antibody or antigen-binding fragment comprises:
- i) a) a heavy chain CDR1 sequence with the consensus sequence G, F, T/N, F, G, Y, S, Y (SEQ ID NO:
- 31);
- b) a heavy chain CDR2 sequence with the consensus sequence I, G, S, G/T, S, S, Y/H, T (SEQ ID NO:
- 32);
- and c) a heavy chain CDR3 sequence with the sequence ARVYSSPGIDY (SEQ ID NO:
- 5);
- and ii) a) a light chain CDR1 sequence with the consensus sequence Q, S, I, S/G, S, Y/T (SEQ ID NO:
- 33);
- b) a light chain CDR2 sequence with the consensus sequence A/G, A, S (SEQ ID NO:
- 34);
- and c) a light chain CDR3 sequence with the sequence QQYYTWVPFT (SEQ ID NO:
- 8).
Dependencies are inferred from the claim text.